Shopping Cart
Remove All
Your shopping cart is currently empty
Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $322 | In Stock | In Stock | |
| 5 mg | $788 | In Stock | In Stock | |
| 10 mg | $1,280 | - | In Stock |
| Description | Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers. |
| Synonyms | M9346A |
| Reactivity | Human |
| Verified Activity | Immobilized hu-FRa-ECD-his at 2 μg/mL (30 μL/well) can bind Anti-FOLR1 Reference Antibody (mirvetuximab) with the EC50 of 9.298 ng/mL. |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 148 kDa (average) |
| Cas No. | 1453084-36-0 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.